Prior to that role Mike supported world-wide Humira manufacturing as the Technical Operations Purification Group Leader at AbbVie’s biologics manufacturing site in Puerto Rico. Prior to joining Anthos Therapeutics, he was the Manufacturing Sciences Purification Group Leader at AbbVie Bioresearch Center in Worcester, MA, where his group provided technical support for a broad range of AbbVie and third party products, including monoclonal antibodies, enzymes, fusion proteins, and antibody drug conjugates. Mike has over 35 years of bioprocessing experience, including process development, tech transfer, process validation, manufacturing technical support, and CMC regulatory support. As an Associate Professor his academic research was supported by grants from the NIH (K08, R01, K24), multiple foundations, and industry. Upon his return to the US, he attended Harvard Medical School and subsequently did his Internal Medicine and Cardiology training at Columbia before joining the faculty. Bloomfield was a founding member and co-chair of the Cardiac Safety Research Consortium (a public private partnership with the FDA, academia and industry) and served as Rapporteur for the ICH E14 implementation working group for 9 years.Īfter finishing a BA in Chemistry at Haverford College, Dan took a Master’s degree in Social Anthropology at Oxford University as a Rhodes Scholar. Dan’s career at Merck culminated as SVP and Therapeutic Area Head for Cardiovascular, Diabetes, Endocrine, and Women’s Health Programs and he was responsible for the central coordination and strategic oversight of Merck’s R&D organization in China across all therapeutic areas. He was actively involved in business development, acquisitions, and numerous licensing opportunities and spent a year as Chief of Staff for Merck’s CEO, Ken Frazier. (NYSE: MRK), that included leadership roles in early and late clinical development and cardiovascular discovery. Dan joined Cardurion in May 2017 as its first CEO after a diverse 14 year career at Merck & Co.

Dan has more than 16 years in drug development, initially at Merck and most recently at Cardurion Pharmaceuticals. Dan is the Chief Medical Officer at Anthos Therapeutics.

Dear Mr. Washington by Lynn Cullen